Larotrectinib

NTRK Fusion Positive Cancer

BayerSmall moleculePhase 1/2Active

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 55/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the NTRK Fusion Positive Cancer cohort.

Asset / Sponsor	Phase	Rating
bay2757556 Bayer	Phase 2	BB
Selitrectinib Bayer	Phase 1	CCC
Regorafenib University of California, San Francisco	Phase 2	CCC
Ceritinib University of California, San Francisco	Phase 2	CCC
Entrectinib University of California, San Francisco	Phase 2	CCC

View all 13 →

Same molecule, other indications

Larotrectinib is also rated in:

non-Hodgkin lymphomaActive

CCC

Indicative · Phase 2

53 / 100

refractory malignant neoplasmActive

CCC

Indicative · Phase 2

53 / 100

lung cancerActive

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.